tirzepatide in mash Consistent improvements liver histology across subgroups in a post hoc analysis of the SYNERGY-NASH trial with tirzepatide and liver enzymes hits

R&D Strategy and Pipeline Investments Source EvaluatePharma Behind the commercial success is Lillys focused R&D on metabolic disease

Pinching the skin gently to create a fold of tissue helps ensure the needle enters the subcutaneous layer rather than muscle, which is especially important on leaner patients or those with less body fat

What do you do that you think your body really appreciates

They set up a policy where compounders could work around FDA approval guidelines in cases of shortages." But right now, there is no shortage of GLP-1 medications, and because companies like Eli Lilly and Novo Nordisk have patents, patients are likely years away from FDA-approved generics